Indication
x POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

See other indications for POMALYST:

This website is intended for U.S. Healthcare Professionals.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

IN A PIVOTAL TRIAL IN WHICH 89% OF PATIENTS WERE REFRACTORY TO LENALIDOMIDE

Nearly 60% of patients responded
to POMALYST® (pomalidomide)
+ dex + daratumumab (DPd).

Nearly 60% ORR and >1 year median DoR with DPd.1

Efficacy results were based on overall response rate as determined by Independent Review Committee using IMWG criteria.

Information about DPd does not appear in the POMALYST Prescribing Information (PI). Please see the daratumumab full PI for a discussion of Important Safety Information at www.darzalexhcp.com/iv.

POMALYST + dexamethasone + daratumumab Indication (DPd)

POMALYST + dexamethasone + daratumumab is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

WARNINGS AND PRECAUTIONS FOR DARATUMUMAB (cont’d)

  • Interference With Cross-Matching and Red Blood Cell Antibody Screening: Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test), which may persist for up to 6 months after the last daratumumab infusion. Type and screen patients prior to starting treatment. Inform blood banks that a patient has received daratumumab.
  • Neutropenia: Monitor complete blood cell counts periodically during treatment. Monitor patients with neutropenia for signs of infection. Consider withholding daratumumab until recovery of neutrophils.
  • Thrombocytopenia: Monitor complete blood cell counts periodically during treatment. Consider withholding daratumumab until recovery of platelets.
  • Interference With Determination of Complete Response: Daratumumab can interfere with the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein.
  • Embryo-Fetal Toxicity: Can cause fetal harm. Advise pregnant women of the potential risk to a fetus and advise females of reproductive potential to use effective contraception.

CI, confidence interval; CR, complete response; dara, daratumumab; dex, dexamethasone; DPd, POMALYST + dexamethasone + daratumumab; DoR, duration of response; IMWG, International Myeloma Working Group; IV, intravenous; ORR, overall response rate; PR, partial response; sCR, stringent complete response; VGPR, very good partial response.

Reference: 1. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc.

Learn about the adverse reactions in the EQUULEUS trial.

View the Safety Profile

See additional information for DPd.

View the MM-014 Trial